United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$236.61 USD
-1.33 (-0.56%)
Updated Apr 22, 2024 11:56 AM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Price, Consensus and EPS Surprise
UTHR 236.61 -1.33(-0.56%)
Will UTHR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UTHR
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
Other News for UTHR
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)
Wells Fargo Sticks to Their Buy Rating for United Therapeutics (UTHR)
United Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform Rating
ISPE Announces 2024 Facility of the Year Awards (FOYA) Category Winners
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference